EPIX vs. GRTX, IXHL, AFMD, CELU, IVA, OGI, ESPR, PYXS, TRVI, and MIST
Should you be buying ESSA Pharma stock or one of its competitors? The main competitors of ESSA Pharma include Galera Therapeutics (GRTX), Incannex Healthcare (IXHL), Affimed (AFMD), Celularity (CELU), Inventiva (IVA), Organigram (OGI), Esperion Therapeutics (ESPR), Pyxis Oncology (PYXS), Trevi Therapeutics (TRVI), and Milestone Pharmaceuticals (MIST). These companies are all part of the "pharmaceutical preparations" industry.
ESSA Pharma vs.
Galera Therapeutics (NASDAQ:GRTX) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, community ranking, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.
ESSA Pharma is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Galera Therapeutics and Galera Therapeutics both had 2 articles in the media. Galera Therapeutics' average media sentiment score of 0.51 beat ESSA Pharma's score of -0.35 indicating that Galera Therapeutics is being referred to more favorably in the media.
36.5% of Galera Therapeutics shares are owned by institutional investors. 8.6% of Galera Therapeutics shares are owned by insiders. Comparatively, 12.0% of ESSA Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
ESSA Pharma received 295 more outperform votes than Galera Therapeutics when rated by MarketBeat users. Likewise, 76.16% of users gave ESSA Pharma an outperform vote while only 57.47% of users gave Galera Therapeutics an outperform vote.
Galera Therapeutics' return on equity of 0.00% beat ESSA Pharma's return on equity.
Galera Therapeutics currently has a consensus price target of $7.75, indicating a potential upside of 154.10%. ESSA Pharma has a consensus price target of $17.00, indicating a potential upside of 461.98%. Given ESSA Pharma's higher probable upside, analysts plainly believe ESSA Pharma is more favorable than Galera Therapeutics.
Galera Therapeutics has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500.
Summary
ESSA Pharma beats Galera Therapeutics on 8 of the 13 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding EPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ESSA Pharma Competitors List
Related Companies and Tools
